Improving the diagnostic performance of troponin assays for acute myocardial infarction in renal impairment
Open Access
Abstract
Background: Serum troponin measurement forms a cornerstone of acute myocardial infarction (AMI) diagnosis. A major challenge is interpretation of an elevated first troponin in patients with impaired renal function. We aimed to (1) evaluate the relationship between estimated glomerular filtration rate (eGFR) and first troponin, (2) characterise the performance of different troponin assays for diagnosing AMI and (3) derive eGFR-specific thresholds for potential clinical use. Methods: We analysed the distribution of troponin values stratified by eGFR and AMI. Diagnostic performance was analysed using the C-statistic. Test detection rate, false positive rate and positive predictive value were calculated for different cut-offs. Results: We included 221 175 patients between 2010 and 2017 from four acute tertiary care hospitals in London, UK, with a median age of 65 years (IQR 49–79). eGFR was90 (C-statistic 0.93) and worst in eGFR2 . Restricting the false positive rate to 15% yields eGFR specific cut-offs of 73, 112 and 184 ng/L, with detection rates of 73%, 70% and 68% in patients with an eGFR of 45–60, 30–45 or 15–30 mL/min/1.73 m 2 . Conclusions: The diagnostic performance of an unadjusted troponin cut-off for AMI falls with worsening renal function. We propose consideration of eGFR specific cut-offs to support more effective triage and early management of suspected AMI in patients with renal impairment. Trial registration number: NCT03507309 .Keywords
Funding Information
- National Institute for Health and Care Research (NIHR300906)
This publication has 27 references indexed in Scilit:
- Performance of the European Society of Cardiology 0/1-Hour Algorithm With High-Sensitivity Cardiac Troponin T Among Patients With Known Coronary Artery DiseaseJAMA Cardiology, 2023
- Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2·4 million patients from 11 countries: The CaReMe CKD studyThe Lancet Regional Health - Europe, 2022
- High-sensitivity cardiac troponin and the diagnosis of myocardial infarction in patients with kidney impairmentKidney International, 2022
- Use of High-Sensitivity Cardiac Troponin in Patients With Kidney ImpairmentJAMA Internal Medicine, 2021
- Invasive versus non-invasive management of older patients with non-ST elevation myocardial infarction (SENIOR-NSTEMI): a cohort study based on routine clinical dataThe Lancet, 2020
- Chronic Kidney Disease and Coronary Artery DiseaseJACC, 2019
- High-sensitivity troponin in the evaluation of patients with suspected acute coronary syndrome: a stepped-wedge, cluster-randomised controlled trialThe Lancet, 2018
- The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference reportKidney International, 2011
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studiesThe Lancet, 2007
- Moderate renal insufficiency and the risk of cardiovascular mortality: Results from the NHANES IKidney International, 2002